Heart and Vessels

, Volume 34, Issue 4, pp 632–640 | Cite as

Radiofrequency catheter ablation prior to percutaneous coronary intervention in patients with atrial fibrillation coexisting with stable coronary artery disease: a single-center pilot study

  • Satoshi KawadaEmail author
  • Atsuyuki Watanabe
  • Yoshimasa Morimoto
  • Koji Nakagawa
  • Nobuhiro Nishii
  • Kazufumi Nakamura
  • Hiroshi Morita
  • Hiroshi Ito
Original Article


Atrial fibrillation (AF) frequently coexists with cardiovascular disease (CAD) in a clinical setting. However, the optimum therapy for AF patients who have concomitant CAD is unclear. We retrospectively examined the efficacy and safety of radiofrequency catheter ablation (RFCA) prior to percutaneous coronary intervention (PCI) in patients with AF who had concomitant stable CAD. Between January 2014 and December 2015, a total 264 patients (179 men; mean age, 65.5 ± 10.1 years) who were referred to undergo a first RFCA procedure were reviewed in this study. Of the 264 patients, 41 (15.5%) had stable CAD detected by multi-detector computed tomography before RFCA. Thirty-seven patients who had AF with stable CAD were divided into two treatment arms: (1) RFCA prior to PCI (n = 13) and (2) PCI prior to RFCA (n = 24) [four patients excluded because of left main coronary artery disease (LMCA) or triple vessel disease (TVD)]. The median follow-up was 14 (IQR 8–19) months. There was no significant difference in AF recurrence rate after the procedure between the RFCA first group and PCI first group (P = 0.515). No symptomatic cardiovascular events occurred the during follow-up period. The PCI first group had a significantly longer duration of triple therapy (188.5 ± 167 days vs 5.6 ± 24.5 days, P = 0.01) and all of the four bleeding events occurred during triple therapy (P = 0.01). The results of this single-center pilot study suggested that prior RFCA in patients with AF coexisting with CAD could have fewer serious bleeding events than prior PCI.


Atrial fibrillation Pulmonary vein isolation Coronary artery disease Radiofrequency catheter ablation Percutaneous coronary intervention 


Compliance with ethical standards

Conflict of interest

Dr. Ito reports grants and personal fees from Daiichi-Sankyo, grants from Sanofi, grants and personal fees from Berringer-Ingelheim, grants and personal fees from Bayer, grants from Pfizer, during the conduct of the study. Dr. Hiroshi Morita and Nobuhiro Nishii are affiliated with the endowed department by Japan Medtronic Inc.


  1. 1.
    Dewland TA, Olgin JE, Vittinghoff E, Marcus GM (2013) Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation 128:2470–2477CrossRefGoogle Scholar
  2. 2.
    Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946–952CrossRefGoogle Scholar
  3. 3.
    Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I (2009) Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol 137:102–107CrossRefGoogle Scholar
  4. 4.
    Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H (2011) Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation—the J-RHYTHM Registry study design. J Cardiol 57:95–99CrossRefGoogle Scholar
  5. 5.
    Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, ESC Scientific Document Group (2017) Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 38:2137–2149Google Scholar
  6. 6.
    Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet (Lond, Engl) 381:1107–1115CrossRefGoogle Scholar
  7. 7.
    Hakalahti A, Biancari F, Nielsen JC, Raatikainen MJ (2015) Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. Europace 17:370–378CrossRefGoogle Scholar
  8. 8.
    Saad EB, d’Avila A, Costa IP, Aryana A, Slater C, Costa RE (2011) Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score </=3: a long-term outcome study. Circ Arrhythm Electrophysiol 4:615–621CrossRefGoogle Scholar
  9. 9.
    Pristipino C, Trani C, Nazzaro MS, Berni A, Patti G, Patrizi R (2009) Major improvement of percutaneous cardiovascular procedure outcomes with radial artery catheterisation: results from the PREVAIL study. Heart (Br Cardiac Soc) 95:476–482CrossRefGoogle Scholar
  10. 10.
    Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619CrossRefGoogle Scholar
  11. 11.
    Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351CrossRefGoogle Scholar
  12. 12.
    Ndrepepa G, Schuster T, Hadamitzky M, Byrne RA, Mehilli J, Neumann FJ (2012) Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 125:1424–1431CrossRefGoogle Scholar
  13. 13.
    Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736–2747CrossRefGoogle Scholar
  14. 14.
    Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084–1089CrossRefGoogle Scholar
  15. 15.
    Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet (Lond Engl 367:1903–1912CrossRefGoogle Scholar
  16. 16.
    Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35:3155–3179CrossRefGoogle Scholar
  17. 17.
    Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423–2434CrossRefGoogle Scholar
  18. 18.
    Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH, RE-DUAL PCI Steeering Committee and Investigators (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513–1524CrossRefGoogle Scholar
  19. 19.
    Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS (2009) Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol 20:988–993CrossRefGoogle Scholar
  20. 20.
    Calkins H, Hindricks G, Cappato R, Kim Y-H, Saad EB, Aguinaga L (2017) 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 14:e275–e444CrossRefGoogle Scholar
  21. 21.
    Prasad SM, Maniar HS, Camillo CJ, Schuessler RB, Boineau JP, Sundt TM (2003) The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures. J Thoracic Cardiovasc Surg 126:1822–1828CrossRefGoogle Scholar
  22. 22.
    Zhao HJ, Zheng ZT, Wang ZH, Li SH, Zhang Y, Zhong M (2011) “Triple therapy” rather than “triple threat”: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 139:260–270CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Cardiovascular MedicineOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
  2. 2.Department of Cardiovascular TherapeuticsOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences2-5-1 Shikata-cho, Kitaku, OkayamaJapan

Personalised recommendations